Global Gastric Ulcers Market, By Diagnosis (Stool Test, Endoscopy, Imaging Tests, Blood Tests, Others), Drug Class (Proton Pump Inhibitors (PPI), H2 Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
Peptic ulcers, also known as stomach ulcers or gastric ulcers, are a type of stomach ulcer that causes abdominal pain and discomfort. Peptic ulcers are divided into two types including stomach ulcers and duodenal ulcers. Gastric ulcers are a typical occurrence in the stomach's inner lining. The loss of the mucus layer that protects the stomach from digestive fluids causes these ulcers. Burping, nausea, vomiting, loss of appetite, and other symptoms of stomach ulcers are common. The type of stomach ulcer determines the treatment, which typically includes proton pump inhibitors and antibiotics.
Data Bridge Market Research analyses that the gastric ulcers market was valued at USD 3.98 billion in 2021 and is expected to reach USD 5.57 billion by 2029, registering a CAGR of 4.30% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
2022 to 2029
2020 (Customizable to 2014 - 2019)
Revenue in USD Billion, Volumes in Units, Pricing in USD
Diagnosis (Stool Test, Endoscopy, Imaging Tests, Blood Tests, Others), Drug Class (Proton Pump Inhibitors (PPI), H2 Antagonists, Antacids, Antibiotics, Cytoprotective Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Ireland), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Allergan (Ireland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Hikma Pharmaceuticals PLC (U.K.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Boehringer Ingelheim International GmbH. (Germany), Dr. Reddy’s Laboratories Ltd. (India), Gilead Sciences, Inc. (U.S.), Amgen Inc. (U.S.), Eli Lilly and Company (U.S.), AbbVie Inc. (U.S.), Lupin (India), Allergan (Ireland)
Stomach ulcers are open sores caused by damage to the stomach lining. Also known as gastric ulcers, stomach ulcers are ulcers that affect the stomach. Typically, treatment involves destroying the H. pylori bacterium if it is present, lowering or eliminating the use of non-steroidal anti-inflammatory drugs (NSAIDs) if possible, and aiding the healing of your ulcer using medication. If the ulcer was induced by NSAIDs, treatment with a proton pump inhibitor (PPI). Alternatives to non-steroidal anti-inflammatory drugs (NSAIDs) may be offered, such as paracetamol. If an H. pylori infection caused the ulcer, antibiotics may be used to treat it. This destroys the germs, preventing the ulcer from returning.
Gastric Ulcers Market Dynamics
- Increasing prevalence of gastric ulcers
The rising prevalence of gastric ulcers across the globe is estimated to enhance the market's growth. A stomach ulcer develops when gastric acid eats away at your stomach's protective lining. The acid causes open sores on the stomach that can bleed and cause pain. Gastric ulcer disease manifests itself in a variety of ways, one of which is stomach ulcers. Drugs that reduce gastric ulcer secretion, such as PPIs and H2 receptor antagonists, as well as acid neutralization agents, such as antacids and antibiotics against H. pylori infection, are used to treat peptic ulcers. However, for effective treatment, these medicines are frequently taken in combination.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of gastric ulcers market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the gastric ulcers market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of gastric ulcers market. Rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market’s growth rate during the forecast period of 2022-2029.
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the gastric ulcers market growth. In the peptic ulcer market, companies are pursuing long-term tactics to acquire a competitive advantage, such as new product launches, collaboration partnerships, and product upgrades. RedHill Biopharma announced the commercial introduction of Talicia, a pill to treat H.pylori infection in patients, in the United States in March 2020. The major pharmaceutical company's declaration is anticipated to boost its market position in the future years.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of gastric ulcers during the forecast period.
On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the gastric ulcers market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This gastric ulcers market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the gastric ulcers market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
In Western countries, stomach ulcers are fairly prevalent. There are around 4 million instances every year in the United States. According to some estimates, one out of every ten people will experience one at some point in their lives. This is due to the fact that many of the factors that contribute to stomach ulcers are ubiquitous in modern society.
Gastric ulcers market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Global Gastric Ulcers Market Scope
The gastric ulcers market is segmented on the basis of drug class, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Proton Pump Inhibitors (PPI)
- H2 Antagonists
- Cytoprotective Agents
- Stool Test
- Imaging Tests
- CT scan
- Blood Tests
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Gastric Ulcers Market Regional Analysis/Insights
The gastric ulcers market is analysed and market size insights and trends are provided by country, drug class, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the gastric ulcers market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the gastric ulcers market because of the rising prevalence of gastric ulcers and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market’s growth rate.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Gastric Ulcers Market Share Analysis
The gastric ulcers market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to gastric ulcers market.
Some of the major players operating in the gastric ulcers market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Allergan (Ireland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Dr. Reddy’s Laboratories Ltd. (India)
- Gilead Sciences, Inc. (U.S.)
- Amgen Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- AbbVie Inc. (U.S.)
- Lupin (India)
- Allergan (Ireland)